Last updated: February 15, 2026
mmary
The drug with NDC 65862-0778 is a biosimilar version of Humira (adalimumab), used primarily to treat autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Market analysis indicates increasing adoption driven by patent expirations and generic biosimilars entering the market. Price projections anticipate significant reductions compared to originator prices, with biosimilar prices expected to stabilize around 50-60% of the reference drug’s cost over the next five years.
Market Overview and Competition
Humira’s patent expiration in the U.S. began in January 2023. Multiple biosimilars, including the product coded NDC 65862-0778, have received FDA approval and are entering the market. Key competitors include Amgen’s Amjevita (adalimumab-atto), Samsung Bioepis’s Hadlima (adalimumab-bwwd), and other biosimilars approved since 2023.
Market share shift reflects a rapid uptake of biosimilars, especially in states with policies favoring cost-effective alternatives. As of Q1 2023, biosimilar sales accounted for approximately 15% of adalimumab prescriptions, with projections to reach 40-50% within two years, following increased formulary acceptance and payer coverage.
Pricing Trends and Projections
Original Humira list price stood at approximately $6,000 per month in 2023. Biosimilar pricing is significantly lower. Early adopters priced biosimilars at approximately 40-55% of the originator, translating to $2,400–$3,300 per month.
Future price trajectories based on international benchmarks and market entry strategies suggest the following:
| Year |
Predicted Average Biosimilar Price (Monthly) |
Notes |
| 2023 |
$2,400–$3,300 |
Market penetration begins |
| 2024 |
$2,000–$2,800 |
Increased competition, discounts, insurer negotiations |
| 2025 |
$1,800–$2,500 |
Price stabilization, value-based pricing models |
| 2026 |
$1,600–$2,200 |
Wide adoption, further discounts |
Regulatory and Reimbursement Environment
The CMS has included biosimilars in the Medicare Part D formulary with preferred status, encouraging their use. States with policies incentivizing biosimilar substitution—like Florida and Ohio—also support faster market penetration.
Insurance providers and pharmacy benefit managers (PBMs) favor biosimilars due to lower costs, influencing formulary placements. This leads to accelerated uptake and downward pressure on prices.
Market Drivers and Barriers
Drivers: Patent expiries of originators, payer and provider interest in cost reductions, favorable regulatory environment, increasing provider and patient acceptance.
Barriers: Brand loyalty, prescriber familiarity, possible supply chain issues, and residual concerns about immunogenicity compared to originators.
Key Market Players and Strategies
- Amgen: As the first biosimilar entrant (Amjevita), pursuing aggressive contracts.
- Samsung Bioepis: Focuses on partnerships with large payers for rapid uptake.
- Sandoz: Offers multiple biosimilars and is expanding manufacturing capacity.
- Originator manufacturer AbbVie: Focuses on lifecycle management and patent litigation.
Financial Impacts for Stakeholders
Hospitals and outpatient clinics are negotiating with payers to favor biosimilar use, shifting revenue models. Manufacturers in this sector aim for market share leadership via cost reductions, scale, and strategic partnerships.
Legal and Patent Dynamics
Patent litigation continues, with some biosimilars facing delays or legal challenges. The expiry schedule of key patents influences market entry timing and pricing strategies.
Summary of Key Data Points:
- Originator (Humira) list price (2023): ~$6,000/month
- Biosimilar price (initial): $2,400–$3,300/month
- Price trajectory (2026): $1,600–$2,200/month
- Biosimilar market share (2023 Q1): 15%
- Projected biosimilar market share (2025): 40-50%
Key Takeaways
- NDC 65862-0778 represents a key biosimilar in a transitioning market following patent expiration.
- Prices are expected to decline steadily as biosimilars gain acceptance and more competitors enter.
- Payer policies heavily influence market uptake and price stabilization.
- Continued patent litigation may impact the timing and volume of biosimilar availability.
- Strategic partnerships and formulary positioning will determine market share and revenue potential.
FAQs
-
When will biosimilars for Humira fully replace the original drug?
Depending on market acceptance, patent litigation outcomes, and regulatory factors, biosimilars could reach 80-90% market share within three to five years.
-
What factors most influence biosimilar pricing?
Competition, payer negotiations, manufacturing costs, and regulatory incentives shape biosimilar pricing.
-
Are biosimilars safe and effective compared to the originator?
Yes. Clinical studies verify biosimilars to be highly similar to the originator in safety and efficacy; regulatory agencies require strict comparability evidence.
-
What are the main barriers to biosimilar adoption?
Prescriber familiarity, patient acceptance, supply chain reliability, and residual concerns about immunogenicity.
-
What legal challenges could delay biosimilar market entry?
Patent litigations and exclusivity periods can delay approvals or limit initial market availability.
Citations
[1] IQVIA, 2023. U.S. Biosimilar Market Report.
[2] FDA, Biosimilar Approval Data, 2023.
[3] CMS, 2023. Medicare Part D formulary guidelines for biosimilars.
[4] Sandoz Biosimilar Pipeline, 2023.
[5] BBB, 2023. Biosimilar Price Trends Analysis.
